ACC 2024 | REDUCE AMI: Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction

Most clinical trials have shown benefits of beta blockers after acute myocardial infraction, including patients with extensive AMI, and these were carried out in the era before AMI was diagnosed with biomarkers and prior to treatment with coronary angioplasty, use of antithrombotic agents and high intensity statins, and angiotensin-aldosterone system inhibitors.

ACC 2024

The aim of this multicenter, randomized study was to assess the potential benefit of treatment with beta-blockers after AMI in patients with conserved left ventricular systolic function in the current era of percutaneous treatment and medical treatment. 

The primary outcome was a combination of all-cause death and non-fatal AMI. Secondary end point was a combination of all-cause death, AMI and hospitalization for cardiac failure. There was a safety end point including hospitalization for bradyarrhythmia, hypotension or syncope, hospitalization for asthma or COPD and hospitalization for stroke. 

5020 patients were randomized; 2508 to receiving beta-blockers (metoprolol or bisoprolol) and 2512 for conventional treatment. Mean age was 65 and most were men. Mean followup was 3.5 years. 35% of patients presented ST elevation AMI. 17% presented left main and three vessel disease, and most received percutaneous coronary intervention (PCI) (96%), while the remaining 4% underwent myocardial revascularization surgery (CABG).

Read also: ACC 2024 | SMART Trial: Self-Expanding or Balloon-Expandable TAVR in Patients with Small Aortic Annulus.

The primary outcome resulted 7.9% for the beta-blocker group vs. 8.3% for the conventional treatment group (HR 0.96; CI 95% 0.79-1.16; p=0.64). There were no differences in secondary and safety end points.

Conclusion 

Among patients with acute myocardial infarction undergoing early coronary angiography with conserved left ventricular ejection fraction (≥50%), treatment with beta-blockers at long term did not present lower risk of all cause death or new AMI or new myocardial infarction vs. no beta-blockers. 

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Beta-blockers after Myocardial Infarction and Preserved Ejection Fraction.

Reference: Troels Yndigegn et al ACC 2024.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Morpheus Global Registry: Safety and efficacy of the long tapered BioMime™ Morph stent in complex coronary lesions

Percutaneous coronary intervention in long coronary lesions continues to represent a technical and clinical challenge, in which the use of conventional cylindrical stents may...

Hybrid Coronary Revascularization versus Conventional Bypass Surgery in Left Main Coronary Artery Disease

Significant left main coronary artery (LMCA) disease continues to represent a therapeutic challenge, particularly in patients with complex multivessel disease and high SYNTAX scores,...

Comparison of strategies: NMA of IVUS, OCT, or angiography in complex lesions

Percutaneous coronary intervention (PCI) in complex lesions continues to represent a technical challenge in contemporary interventional cardiology. Angiography, although it remains the most widely...

Dynamic Coronary Roadmap: does it really help reduce contrast use?

Contrast-induced nephropathy remains a relevant complication of percutaneous coronary interventions (PCI), particularly in patients with multiple comorbidities and complex coronary anatomies. Dynamic Coronary Roadmap...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Transcatheter Paravalvular Leak Closure: Mid-Term Outcomes and Prognostic Factors

Paravalvular leaks (PVL) are a frequent complication following surgical valve replacement, occurring in 5% to 18% of prosthetic valves. Incidence varies according to valve...

After a Major Bleeding Event in Atrial Fibrillation: When Should Left Atrial Appendage Closure Be Considered?

Atrial fibrillation (AF) in patients who experience a major bleeding event represents a complex clinical scenario in which percutaneous left atrial appendage closure (LAAC)...

New Balloon-Expandable Aortic Valve: 30-Day Outcomes in Patients with Small Aortic Annulus

As transcatheter aortic valve implantation (TAVI) continues to expand toward younger patients with longer life expectancy, factors such as valve hemodynamic performance, durability, and...